Photo of Juan Badimon

Juan Badimon

  • PROFESSOR Medicine, Cardiology
Print ProfilePrint Profile


    Juan Jose Badimon, PhD, is Professor of Medicine and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute, The Mount Sinai School of Medicine, New York. Dr. Badimon was born in Barcelona, Spain. He graduated from the University of Barcelona in 1982.  In the same year, he moved to the United States where he served as Post-doctoral research Fellow at Mayo Clinic until 1984. Then he moved on to Mount Sinai  New York (1984 -1990), Massachusetts General Hospital, Boston (1990-1994). In 1994 he returned to Mount Sinai School of Medicine in New York.

    Among Honors awards received; he is a fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA). He was awarded a Doctor Honoris Causa by the Catholic University of Buenos Aires, Visiting Professor Ad-Honorem of the Central University of Bogota, Colombia;  Honorary Professorship of the Tucuman School of Medicine, Argentina;  Honorary Memberships of the Spanish and Venezuelan Society of Arteriosclerosis, as well as the Societies of Cardiology of Chile, Argentina and Mexico.

    Dr. Badimon's group research interests are focused on cardiovascular biology and the pathogenesis and treatment of atherothrombosis in general. More specifically, his lab is interested on the role of lipids and HDL in the genesis and progression of atherosclerotic lesions as well as the clinical manifestations of atherothrombosis.  On this regard, he has done interesting work on the role played by the vulnerable plaque and vulnerable blood to define the vulnerable or high-risk patient.  Within this line of research he is involved in the optimizing of the use of the already available antithrombotic agent to reduce the thrombotic implications of atherothrombosis disease and in the development of more potent and efficient new antithrombotic agents. The role of the tissue factor pathway in atherothrombosis, as well as the potential therapeutic implications of its inhibition, is one of his lab major interests. His lab has been very instrumental in studying the activities and optimizing the therapeutic doses of some of the most recent inhibitors of the Tissue Factor pathway (thrombin inhibitors, anti FXa and/or anti FVIIa). More recently he has been involved in the use of non-invasive imaging modalities (MRI and CT) for detecting early atherosclerotic lesions as well as monitoring the effectiveness of therapeutic approaches in arteriosclerosis and thrombosis.

    Dr. Badimon has published more than 280 peer-reviewed articles in the areas of athero-thrombosis, imaging and cardiovascular diseases in general. He serves as reviewer for more than 10 top journals in cardiovascular diseases.

    He has trained more than 30 fellows from different countries throughout his career. The majority of these fellows after their stage with him have achieved seniors and independent positions in their new appointments.


  • 2006 -
    Recipient of the John Paul II Medal, Krakow, Poland

  • 2004 -
    Researcher of the Year
    The Royal Academy of Pharmacy of Spain

  • 2003 -
    Xth Joan D'Alos Award, Barcelona, Spain

  • 1997 -
    VIIth Internship Award
    Sanofi Association for Thrombosis and Haemostasis, Florence, Italy

  • 1989 -
    Dr. Hermman C.B. and Suzanne Denber Award for Excellence in Cardiovascular Research


Dr. Badimon's laboratory interests are focused in three majors aspects: 1) Role of antithrombotic agents in the genesis and treatment of acute coronary syndromes. A major line of research of our laboratory is to investigate the pathologic processes involved on the acute coronary syndromes as well as the new therapeutic possibilities. More specifically, we are studying the role of thrombin in the thrombotic process and the potential therapeutic implication of the thrombin inhibtion. Preclinical and clinical studies on the effects of direct and specific thrombin inhibitors and other inhibitors of the Tissue Factor pathway ( Inhibitors of Tissue Factor, FVIIa and/or FXa)are being studied. These studies are being carried out using a perfusion chamber originally developed in our laboratory. This device is well accepted in the literature and it is being used by several groups. We are currently involved in two clinical Phase II studies involving the antithrombotic effects of inhibitors of coagulation Factor Xa. Flow cytometry, platelet aggregation, histology and specific ELISAS are being used to investigate the mechanisms responsible for the observed antithrombotic effects 2.-Pathogenesis of Restenosis after Percutaneous Interventions.- Previous studies by our group and others have indicated a critical role for thrombosis and increased cell proliferation in the arterial response to injury and thus, in restenosis post interventions. The potential therapeutic implications of antithrombotic agents and inhibitors of the cell cycle signaling ( cdki's) are being studied. New modalities of local delivery are being investigated on the possibility of optimizing the beneficial effects of these pharmacological or molecular probes and simoultaneously reducing their potential side-effects. The availability of an effective local delivery modality could have a significant impact in the studies using gene delivery approaches in the prevention of restenosis. More recently we are also studying the possible implication of apoptosis both in the ethiopatogenesis of restenosis and its potential modulation as a novel approach to the prevention of restenosis post PCI or stent implantation. Several experimental in vivo and in vitro models have being developed and in use for these purposes.


Ibanez B, Cimmino G, Benezet-Mazuecos J, Santos-Gallego CG, Pinero A, Prat-Gonzalez S, Speidl WS, Fuster V, Garcia MJ, Sanz J, Badimon JJ. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 2008;.

Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-IMilano (ETC-216) administration. J Am Coll Cardiol 2008; 51: 1104-1109.

Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration during persistent coronary occlusion results in increased myocardial salvage: an analysis of ischemic myocardium at risk using cardiac MRI. Circulation 2007; 115: 2909-2916.

Zafar MU, Vorchheimer DA, Gaztanga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-888.

Ibanez B, Vilahur G, Speidl W. Rapid Change in Plaque Size and Molecular Footprint Follow. JACC 2008; 18(51): 1104-1109.

Cimmino G, Ibanez B, Vilahur G, Speidl W, Fuster V, Badimon L, Badimon J. Up-Regulation of Reverse Cholesterol Transport Key Players and Rescue from Global Inflammation by ApoA-I. J Cell Mol Med 2009; 13: 3226-3235.

Cimmino G, Chen W, Speidl W, Giannarelli C, Ibanez B, Fuster V, Hajjar R, Walsh C, Badimon J. Safe and sustained over-expression of functional ApoA-I/HDL in ApoA-I null mice by muscular AAV8 gene transfer. J Cardiovasc Pharmocol 2009; 54: 405-411.

Zafar M, Ibanez B, Choi B, Vorchheimer D, Pinero A, Jin X, Sharma R, Badimon J. An oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel in a randomised phase I study. Thromb Haemost 2010; 103: 205-212.

Zafar M, Paz-Yepes M, Shimbo D, Vilahur G, Burg M, Chaplin W, Fuster V, Davidson K, Badimon J. Anxiety is a Better Predictor of Platelet Reactivity in Acute Coronary Syndrome Survivors than Depression. European Heart Journal 2010;.

Speidl W, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia M, Fuster V, Goldman M, Badimon J. Apolipoprotein A-I Milano Rapidly Reverses Aortic Valve Stenosis and Decreases Leaflet Inflammation in a Hypercholesterolemic Rabbit Model. European Heart Journal 2010;.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Badimon during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Boehringer Ingelheim Corporation

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Atran Berg Laboratory Building Floor 6 Room 20
1428 Madison Avenue
New York, NY 10029